A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

18 Apr 2024 Results evaluating the efficacy, tolerability and safety of different doses of ES-481 in adults with drug resistant epilepsy presented at the 76th Annual Meeting of the American Academy of Neurology 2024
01 Mar 2023 Planned End Date changed from 31 Oct 2022 to 1 Dec 2023.
01 Mar 2023 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com